Introduction to the latest policy on the medical insurance reimbursement price of Entrectinib in 2025

Entrectinib is a targeted therapy drug mainly used to treat NTRK fusion-positive or ROS1 -positive advanced non-small cell lung cancer (NSCLC ) and other solid tumors. As its effectiveness in the field of tumor treatment is gradually recognized, the drug has completed marketing approval in China in recent years and has been included in the National Medical Insurance Drug List. This means that domestic patients can obtain this innovative targeted drug at a relatively low price through hospital channels if they meet the conditions for medical insurance reimbursement.

As of2025, the entrectinib medical insurance reimbursement policy has been promoted nationwide. According to the current policy, entrectinib is listed as a Class B drug in medical insurance. The specific reimbursement ratio is determined by local medical insurance policies, which is generally around 70%. Taking the price of the original drug in the domestic market as about 2 / box (100mg*30 capsules) as an example, after being reimbursed by medical insurance, the patient's out-of-pocket portion can be reduced to about 6,000 yuan, reducing the family's treatment burden. The access conditions for medical insurance include: patients must be confirmed by NTRK or ROS1 fusion positive gene testing, and there is no better alternative treatment.

It should be noted that there is usually a certain drug approval process for reimbursement of entrectinib by medical insurance. Some areas require special medical insurance drug approval procedures. Doctors need to provide genetic testing reports and detailed condition assessments when issuing prescriptions. The implementation of medical insurance varies in different regions. It is recommended that patients or family members communicate with the medical insurance office of the hospital in advance to ensure that the materials are fully prepared to avoid affecting the reimbursement process.

For patients who cannot obtain medical insurance or who want to further reduce the cost of medication, they may also consider purchasing drugs through overseas channels Overseas channels. At present, the Lao version of the generic entrectinib drug is on the market, with the specification of 100mg*60 capsules/box. The price is about more than 1,000 yuan, and the drug ingredients are basically the same as the original drug. Although this version is affordable, it needs to be obtained through formal channels to ensure drug quality and safety and avoid the risk of purchasing on behalf of others that may affect the treatment effect. In short, whether through medical insurance or purchasing agents, patients should use medications scientifically and rationally under the guidance of doctors.

Reference materials:https://www.roche.com/products/rozlytrek